Aridis Pharmaceuticals, Inc

ImmunoGen, Inc. and Protagonist Therapeutics, Inc. accomplished in early April what has become increasingly difficult for public biotechnology companies to do when they accessed significant amounts

Aridis Pharmaceuticals, Inc ’s AR-301 has failed a pivotal ventilator-associated pneumonia (VAP) trial due to problems with patient enrolment but analysts are optimistic about what the data could mean

While ContraFect Corporation. ’s exebacase may still have a viable clinical development pathway, the company has found its overall clinical development program knocked back several places after a dec

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AstraZeneca Offloads Phase III-Ready Su